We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Stock Moves -1.39%: What You Should Know
Read MoreHide Full Article
The latest trading session saw Moderna (MRNA - Free Report) ending at $101.05, denoting a -1.39% adjustment from its last day's close. This change was narrower than the S&P 500's daily loss of 1.61%. On the other hand, the Dow registered a loss of 0.82%, and the technology-centric Nasdaq decreased by 2.23%.
Heading into today, shares of the biotechnology company had lost 8.92% over the past month, lagging the Medical sector's gain of 1.5% and the S&P 500's gain of 3.28% in that time.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. On that day, Moderna is projected to report earnings of -$0.82 per share, which would represent a year-over-year decline of 122.71%. Meanwhile, our latest consensus estimate is calling for revenue of $2.5 billion, down 50.84% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 14.23% rise in the Zacks Consensus EPS estimate. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 99, positioning it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Stock Moves -1.39%: What You Should Know
The latest trading session saw Moderna (MRNA - Free Report) ending at $101.05, denoting a -1.39% adjustment from its last day's close. This change was narrower than the S&P 500's daily loss of 1.61%. On the other hand, the Dow registered a loss of 0.82%, and the technology-centric Nasdaq decreased by 2.23%.
Heading into today, shares of the biotechnology company had lost 8.92% over the past month, lagging the Medical sector's gain of 1.5% and the S&P 500's gain of 3.28% in that time.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. On that day, Moderna is projected to report earnings of -$0.82 per share, which would represent a year-over-year decline of 122.71%. Meanwhile, our latest consensus estimate is calling for revenue of $2.5 billion, down 50.84% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Moderna. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 14.23% rise in the Zacks Consensus EPS estimate. Moderna is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 99, positioning it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.